top of page
ABOUT US
Founded in 2021 by Dr. Ke Cheng, Xsome Biotech has licensed key IPs from North Carolina State University. Xsome Biotech seeks to develop exosome therapeutics and novel drug delivery carriers for a variety of diseases. The company is a lead candidate (XO101 lung stem cell based secretome) and has gained IND approval for treating patients with ARDS.
OUR SCIENCE
Xsome Biotech's ResEV platform technology allows precise delivery of drugs to the lung paranchyma via inhalation. There are several fold of enhancement when compared to liposomes. We have also pioneered the use of EVs for lung regeneration.
LATEST NEWS
Learn how Xsome is making a difference.
bottom of page